How Private Equity Is Buying Up Physical Therapy Chains

Lucas: So you go to your doctor with a bad knee, and before you leave, they hand you a card for a physical therapy chain - ATI, Select Medical, something like that. Have you ever wondered who owns that chain? Luna: I assumed it was either a hospital system or some local practice. But you're telling me there's a private equity story behind it.

Lucas: There almost always is. Physical therapy has become one of the most aggressively consolidated slices of outpatient healthcare over the past decade. And it's a textbook private equity roll-up play - predictable cash flows, fragmented market, huge opportunity to centralize billing and cut costs. Luna: How big are we talking?

How many clinics have been bought up? Lucas: According to a 2025 analysis from the Private Equity Stakeholder Project, about 65 percent of all physical therapy clinics in the US are now owned by private equity-backed platforms. That's up from maybe 20 percent a decade ago. The largest operator, ATI, runs over 900 locations.

Select Medical has around 1,800 outpatient centers, many of them pt focused. And then you've got mid-market players like Upstream Rehabilitation with about 500. Luna: That's a lot of clinics. What makes physical therapy so attractive to PE in the first place?

Lucas: Three things. First, the revenue is recurring and insurance-based - Medicare, commercial plans, workers' comp - so it's not as exposed to the kind of consumer spending swings you see in, say, cosmetic dentistry or elective surgery. Second, the clinics themselves are relatively cheap to acquire. A standalone practice might go for two to three times its annual EBITDA, which is modest compared to other healthcare roll-ups.

And third, there's a massive administrative efficiency gain. Most independent PTs run their own billing, scheduling, and compliance. A centralized platform can cut those overhead costs by 15 to 20 percent. Luna: That's the classic buy-and-build playbook.

Buy a bunch of small practices, centralize the back office, and flip the combined entity to a bigger PE firm or a strategic buyer at a higher multiple. Lucas: Exactly. The typical strategy is to start with a platform acquisition - maybe a chain of 20 to 30 clinics - and then bolt on smaller practices one by one. The bolt-ons usually trade at lower multiples than the platform, so every acquisition adds accretion.

And because the clinics operate under the same insurance contracts, you can negotiate better reimbursement rates as you scale. Luna: Quick honest thing - we do this show ad-free, and it stays that way because a handful of listeners chip in through buy me a coffee dot com slash fexingo. If our conversations about private equity have helped you think about a business decision or just understand your own healthcare better, that's the kind of support that keeps us going. Luna: Yeah, and it's genuinely not a big ask - just whatever feels right.

Now, back to the PT roll-up story. You mentioned reimbursement rates get better with scale. But isn't there a ceiling? Medicare sets rates nationally, so you can't negotiate there.

Lucas: Right, Medicare is a fixed fee schedule. But commercial insurers - think UnitedHealthcare, Aetna, Cigna - those rates are negotiated. If you're a 500-clinic chain, you have real leverage. You can say, 'If you don't give us a 10 percent rate increase, we'll pull all 500 clinics out of your network.'

And that's a credible threat because patients don't want to lose access. So the pe backed chains have been able to push commercial rates 15 to 25 percent higher than what independent clinics get. Luna: That's a huge margin driver. But it also creates a tension - the more you squeeze insurers, the more they push back.

And there's the regulatory angle too. Physical therapy referrals are subject to Stark Law and anti-kickback statutes. If a pe owned clinic gets too cozy with referring physicians, that's a problem. Lucas: It is, and we've seen that blow up.

In 2022, a mid-sized Texas-based roll-up called RehabCare Partners collapsed after an investigation revealed that they had been paying physicians per referral disguised as 'medical directorships.' The DOJ fined them $18 million, the lenders pulled the credit line, and the entire platform was sold for pennies on the dollar to a competitor. That's the risk of rolling up too fast without compliance infrastructure. Luna: So the thesis works until it doesn't.

What's the current state of the market? Are valuations still high? Lucas: They came down a bit after the 2022 interest rate hikes, but they've stabilized. A well-run platform with 100-plus clinics still trades at around 8 to 10 times EBITDA.

That's down from the peak of 12 to 13 times in 2021, but still healthy. The bigger question is whether the consolidation has reached a natural limit. There are only so many independent clinics left to acquire. Some analysts estimate that the top ten players now control over 40 percent of the market.

That means the easy bolt-ons are gone. Luna: So what's the next move for PE firms that own these platforms? They can't keep buying forever. Lucas: They're pivoting to two things.

First, expansion into adjacent services - occupational therapy, speech therapy, even some home health. That lets them cross-sell to the same patient base. Second, they're investing in technology: telehealth platforms, ai driven scheduling, even remote monitoring tools that can reduce the need for physical visits. The idea is to make each clinic more efficient rather than just adding more clinics.

Luna: That makes sense. But it also changes the investment thesis. You're no longer just rolling up mom and pops; you're building a tech-enabled healthcare company. That requires different expertise.

Lucas: Absolutely. And that's where some of the newer entrants have an edge. Firms like General Atlantic and Summit Partners have been backing tech-forward PT startups that own their own clinics - companies like Vori Health or Sword Health. These are more vertically integrated, with a digital front door and a network of employed therapists.

They're not just buying old clinics; they're building new ones. Luna: So what does this mean for the patient? If you walk into a pe owned PT clinic, are you getting worse care? Lucas: There's some evidence of higher patient to therapist ratios and more standardized treatment protocols, which can feel less personal.

A 2024 study in JAMA Internal Medicine found that patients at pe owned clinics had slightly worse functional outcomes after twelve weeks compared to independent clinics - not dramatically worse, but statistically significant. The trade-off is access: PE clinics tend to have longer hours, more locations, and shorter wait times. Luna: So it's the classic consolidation trade-off: efficiency and scale versus personalized care. The question is whether the market - patients, insurers, regulators - will accept that trade-off long enough for PE to exit.

Lucas: That's the billion-dollar question. Most of these platforms were built with five-to-seven-year hold periods. The first wave of deals from 2017 to 2019 should be coming up for exit now. But the IPO market has been tepid, and strategic buyers - like Optum or HCA - are being cautious.

So some of these PE firms are extending their holds, refinancing their debt, and hoping for a better window in 2027 or 2028. Luna: And if that window doesn't open? We could see some distressed sales, like what happened with RehabCare Partners but on a larger scale. Lucas: Exactly.

There's a lot of leverage in these platforms - typical debt loads are four to five times EBITDA. If reimbursement rates get cut or utilization drops, the debt service becomes a real problem. The next recession could be a major test for the whole model. Luna: So the roll-up story is still unfolding.

It's not just a simple buy and flip; it's a bet on the long-term value of scale in outpatient rehab. Lucas: Right. And whether that bet pays off depends on factors PE firms can't fully control: Medicare policy, antitrust enforcement, and the willingness of patients to accept a more industrial healthcare experience. It's one of the most interesting corners of private equity right now, precisely because it's not a slam dunk.

Luna: I think that's what makes it worth watching. If you're a limited partner looking at PE returns, the next five years will tell you whether the physical therapy roll-up was a brilliant strategy or a cautionary tale. Lucas: And if you're a patient - well, next time you get that card for a PT chain, you'll know exactly who's behind it.